Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease

por Guerra Veloz, María Fernanda, Argüelles-Arias, Federico, Castro Laria, Luisa, Maldonado Pérez, Belén, Benítez Roldan, Antonio, Perea Amarillo, Raúl, Merino Bohórquez, Vicente, Calleja, Miguel Angel, Caunedo Álvarez, Ángel, Vilches Arenas, Ángel
Publicado 2018

Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data

por Guerra Veloz, María Fernanda, Belvis Jiménez, María, Valdes Delgado, Teresa, Castro Laria, Luisa, Maldonado Pérez, Belén, Perea Amarillo, Raúl, Merino Bohórquez, Vicente, Caunedo Álvarez, Ángel, Vilches Arenas, Ángel, Argüelles-Arias, Federico
Publicado 2019

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results

por Argüelles-Arias, Federico, Guerra Veloz, Maria Fernanda, Perea Amarillo, Raul, Vilches-Arenas, Angel, Castro Laria, Luisa, Maldonado Pérez, Belen, Chaaro Benallal, Dina, Benítez Roldán, Antonio, Merino, Vicente, Ramirez, Gabriel, Calleja-Hernández, Miguel Angel, Caunedo Álvarez, Angel, Romero Gómez, Manuel
Publicado 2017